Source: http://www.readbag.com/accessdata-fda-cdrh-docs-pdf8-k082462
Timestamp: 2019-05-23 09:56:12
Document Index: 749541331

Matched Legal Cases: ['arts 800', 'art 807', 'arts 801', 'art 820', 'art 807', 'art 801', 'art 801']

Read K082462.pdf
Read K082462.pdf text version
5. 510(k) Summary
(1) Submitted by: Diamond Diagnostics 333 Fiske St. Holliston, MA 01 746 (2) Contact Person:
GemLyte Electrolyte Analyzer
Liann Voo, Director of Quality Assurance and Scientific Development-629 508-429-0450 (x 351) Phone: 508-429-0452 Fax: Ivoo(a-diamonddiagnostics.com E-mail: (3) Summary Prepared: August 25, 2008 (4) Device Trade Name: Gem Lyte Electrolyte Analyzer Na/+C-C+/i (5) Regulatory Information Description Sodium Test System Potassium Test System Chloride Test System Calcium Test System Lithium Test System (6) Predicate Devices: Description AVL9180 IL 943 Flame Photometer EasyLyte 925 Chloridometer 510O(k) K961458 K823480 K000926 K81 0615 CFR Section 862.1665 862.1600 862.1170 862.1145 862.3560 Device Class Class 11 Class 11 Class 11 Class 11 Class 11
Product Code JGS CEM CGZ JFP JIH
Analytes Sodium, Potassium, Chloride, Calcium and Lithium Sodium, Potassium, Chloride Sodium, Potassium, Chloride Chloride
Statement of Technology Characteristics of the Device Compared to Predicate Device Operating Principle +K000926 Potentiometric Na+, K+, Cl-, Ca+ Li+ Predicate Device K961458 GemLyte Same
(7) Device Description and Indications for Use: The GemLyte is an automated, microprocessor-controlled analyzer which utilizes ion-selective electrodes for the measurement of sodium, potassium, chloride, calcium and lithium in serum, plasma, whole blood and prediluted urine samples. GemLyte analyzer is designed with the user in mind, it is fully automated with simple 'Yes' or 'No' commands for menu navigation. This simple interface insures that not only will the analyzer be easy to use for quick analysis, (less than a minute for samples), but also that the testing of samples can be done by even non-skilled operators with relative ease. The analyzer self-calibrates using Diamond Diagnostics Fluid Pack (510(k) 013850) every 4 hours through out the day or on request. Sodium, potassium, chloride and calcium are commonly measured for use in the diagnosis and management of patients with a broad range of renal, metabolic and cardiovascular disorders. Lithium is a drug used to treat mental illness. Mission controls (510 (k) 033063) are the recommended quality control material to be used daily. The GemLyte Potassium Assay is intended to measure potassium in whole blood, serum, plasma, and urine on the GemLyte Electrolyte Analyzer. Measurements obtained by this device are used to monitor electrolyte balance in the diagnosis and treatment of diseases conditions characterized by low or high blood potassium levels. The GemLyte Sodium Assay is intended to measure sodium in serum, plasma, and urine on the GemLyte Electrolyte Analyzer. Measurements obtained by this device are used to monitor electrolyte balance in the diagnosis and treatment of aldosteronism (excessive secretion of the hormone aldosterone), diabetes insipidus (chronic excretion of large amounts of dilute urine, accompanied by extreme thirst), adrenal hypertension, Addison's disease (caused by destruction of the adrenal glands), dehydration, inappropriate antidiuretic hormone secretion, or other diseases involving electrolyte imbalance. The GemLyte Chloride Assay is intended to measure the level of chloride in plasma, serum, sweat, and urine. Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders such as cystic fibrosis and diabetic acidosis. The GemLyte Calcium Assay is intended to measure the total calcium level in serum. Calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany (intermittent muscular contractions or spasms). The GemLyte Lithium Assay is intended to measure lithium (from the drug lithium carbonate) in serum or plasma. Measurements of lithium are used to assure that the proper drug dosage is administered in the treatment of patients with mental disturbances, such as manic-depressive illness (bipolar disorder). (8) Technological Characteristics of the Device: Principal of Measurement The principles of measurements used in the GemLyte Electrolyte Analyzer are identical to those principles existing in the electrolyte analyzers K000926 (EasyLyte) and K961458 (AVL 9180) and are substantially equivalent to the K823480 (ILFlame Photometer) and K810615 (925 Chloridometer)
Calibration: The GemLyte performs a 2-point calibration (3-point calibration iflithium) every 4 hours or software permits calibration on demand. A 1-point calibration is performed automatically with each measurement. Technical Specifications: Sample Types: Sample Size: Analyzer tests samples for Na+/K+/Cl'/Ca+/Li+
Whole Blood, Serum, Plasma or Urine 95uL blood, plasma, serum 95uL 1:3 dilution of urine Matrix
B/P/S/Q U
Measurement Range: Parameter
40 - 200 mmol/L 1 - 300 mmol/L
CliCa++
B/P/S/Q U B/P/S/Q
1.5 - 15 mmol/L 5 - 120 mmol/L
50 - 200 mmol/L 1 - 300 mmol/L 0.3 - 5 mmol/L
B/P/S/Q
0.2 - 5.5 mmol/L
P = Plasma U = Urine S = Serum
B = Whole blood Q = Aqueous QC
Blood, Plasma, Serum, Aqueous QC Na+: 0.1 mmol/L 0.01 mmol/L or K+: 0.1 mmol/L CI': 0.1 mmol/L 0.01 mmol/L or Ca*+ : 0.1 mmol/L 0.01 mmol/L or Li+: 0.1 mmol/L Urine Na+: 0 mmol/L K+: 0.1 mmol/L
CI-: 0 mmol/L
Reproducibility: * Na C.V. ·&lt;1% Within Range (n=30) Between Run (10 days) C.V. &lt;2% Blood, Plasma, Serum K+ C.V. &lt;1.5% C.V. &lt;3% CI' C.V. &lt; 2% C.V. &lt; 3% Ca&quot;* SD &lt;0.02 SD &lt;0.06 Li+ SD &lt;0.03 SD &lt;0.09
C.V. &lt; 5% Within Range (n=30) Between Run (10 days) C.V. &lt; 5%
C.V. &lt; 5% C.V. &lt; 5%
Analysis Time Calibration
57 seconds Every 4 hours on demand 2 point calibration Na+,K+,CI-,Ca 3 point calibration Li +
Power 120 VAC 220-240 VAC (Factory set)
5 Hz, 6 A or 24 Hz, 2 A
Size and Weight 12.4&quot; (31.5cm) W x 13.2&quot; (33.5cm) H x 11.6&quot; (29.5cm) D,13 lbs. (&lt;6 kg)
(9) Summary of nonclinical tests submitted with the premarket notification for device. Precision Within-Run Precision is determined for each different sample types, blood, serum and urine, by collecting multiple replicates of each sample type, 30, within a single period of time with out re-calibration of the instrument. Samples of blood and serum are measure in standard blood/serum mode while urine samples are measured in 'Urine Mode'. The standard deviation (SD) and Coefficient Variation (%CV) are calculated. Results are within performance specifications which are not different from the predicate device, AVL 9180(K961458). Na+ K+ ClCa ++ Li+ Blood/Plasma/Serum C.V. &lt;0.6% C.V. &lt; 1.5% C.V. _&lt; 1% SD &lt;0.02 SD &lt;0.04 Urine (1:10 dilution) C.V. &lt; 5% C.V. &lt; 5% C.V. &lt; 2%
Between-Run or Total Precision is determined by testing 2 runs per day (AM &amp; PM) with 2 replicates per run for 10 days for each sample type. The standard deviation (SD) and/or Coefficient of Variation (%CV) are calculated. Results are summarized below and are similar to predicate device, AVL 9180(K961458) and with in specifications. Na+ K+ ClCa ++ Li+ Serum/Blood/Serum C.V. ·&lt;1.5% C.V. &lt; 3% C.V. &lt; 3% SD &lt;0.06 SD &lt;0.09 Urine (1:3 dilution) C.V. &lt;4% C.V. &lt; 5% C.V. &lt; 3%
Note: Because potassium in whole blood is unstable, and clinically significant changes are observed within 2 hours of sample collection, a total imprecision test was conducted using multiple instruments (4). Results were collected over a period of an hour. Linearity Whole blood, Plasma, Serum and Urine are linear across the claimed performance range. A minimum of 5 levels were tested for each type of sample. Dilutions were made from starting stock solutions and regression analysis done. Correlation coefficients were all greater than 0.99.
(10) Summary of clinical tests submitted with the pre-market notification for the device. Clinical testing was conducted to demonstrate the correlation of Diamond Diagnostics GemLyte Analyzer to predicate devices operated by trained personnel. All sample types, whole blood, plasma, serum and urine were collected for testing on the Gem Lyte as well as another predicate device, the AVL 9180. Regression analysis show good correlation to predicate devices for all sample types, whole blood, plasma, serum and urine with correlation coefficients typically greater than 0.99.
Studies were conducted comparing the Diamond GEMLYTE to the Roche 9180 with whole blood, plasma, serum and spot urine samples. Whole Blood in mmol/L Parameter Sodium Potassium Chloride Calcium Lithium Plasma in mmol/L
Slope 0.988 0.972 1.011 0.994 0.983
Intercept 1.04 0.223 -0.49 0.019 -0.049
2 R 0.9962 0.9957 0.9882 0.9885 0.9919
Range 42.3 - 188.1 1.51 - 14.46 54.0 - 191.4 0.304-4.514 0.255 - 5.410
n 128 112 123 124 123
Steyx 1.13 0.166 1.76 0.076 0.079
Parameter Sodium Potassium Chloride Calcium Lithium Serum in mmol/L Parameter Sodium Potassium Chloride Calcium Lithium
Slope 0.987 1.006 1.022 0.971 0.993
Intercept 0.87 -0.014 -3.23 0.042 0.002
R 0.9977 0.9973 0.9879 0.9915 0.9878
Range 43.5 - 194.4 1.55- 13.97 55.2 - 193.2 0.363 - 4.386 0.298 - 5.071
n 105 107 115 123 115
Steyx 1.06 0.178 2.58 0.059 0.092
Slope 0.99 0.981 1.021 0.970 1.004
Intercept 0.03 0.085 -2.57 0.036 0.092
R2 0.9964 0.9979 0.9687 0.9842 0.9876
Range 44.6- 196.9 1.58 - 14.64 50.7- 185.7 0.655 - 4.309 0.213 - 5.149
n 122 127 125 120 131
Steyx 1.37 0.118 3.79 0.082 0.122
Urine (Spot) in mmol/L Parameter Sodium Potassium Chloride Slope 0.983 0.965 0.976 Intercept -2.57 0.34 -1.86
2 R 0.9843 0.9934 0.9807
Range 8- 296 5.3 - 118.2 15 - 272
n 118 108 118
Steyx 8.42 2.22 8.99
Conclusions drawn from the clinical and non-clinical testing.
Analysis of the comparative measurement presented in the 510(k) for this device, together with the linearity and precision data collected during these clinical and non-clinical trails demonstrates that the Diamond Diagnostics + GemLyte ISE Analyzer (with Na +, K+, C, Ca + , Li) is safe, effective and equivalent to the predicate device to which it is compared.
Diamond Diagnostics, Inc. c/o Liann Voo 333 Fiske St. Holliston, MA 01746 Re: k082462 Trade Name: GemLyte Electrolyte Analyzer Regulation Number: 21 CFR 862.1665 Regulation Name: Sodium Test System Regulatory Class: Class II Product Codes: JGS, CEM, CGZ, JFP, JIH Dated: January 27, 2009 Received: January 28, 2009
Dear Ms. Voo: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, &quot;Misbranding by reference to premarket notification&quot; (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html. Sincerely yours, · yC. Harper, Ph.D. Co Ac g Director Division of Chemistry and Toxicology Office of In Vitro Diagnostics Device Evaluation and Safety Center for Devices and Radiological Health
510(k) Number (if known): k082462 Device Name: GemLyte Electrolyte Analyzer Indication For Use: The GemLyte is an automated, microprocessor-controlled analyzer which utilizes ion-selective electrodes for the measurement of sodium, potassium, chloride, calcium and lithium in whole blood, plasma and serum, and prediluted urine samples. The GemLyte Potassium Assay is intended to measure potassium in whole blood, plasma, serum, and urine on the GemLyte Electrolyte Analyzer. Measurements'obtained by this device are used to monitor electrolyte balance in the diagnosis and treatment of diseases conditions characterized by low or high blood potassium levels. The GemLyte Sodium Assay is intended to measure sodium in whole blood, plasma, serum, and urine on the GemLyte Electrolyte Analyzer. Measurements obtained by this device are used to monitor electrolyte balance, in the diagnosis 'and treatment of aldosteronism (excessive secretion of the hormone aldosterone), diabetes insipidus (chronic excretion of large amounts of dilute urine, accompanied by extreme thirst), adrenal hypertension, Addison's disease (caused by destruction of the adrenal glands), dehydration, inappropriate antidiuretic hormone secretion, or other diseases involving electrolyte imbalance. The GemLyte Chloride Assay is intended to measure the level of chloride in whole blood, plasma, serum, and urine. Chloride measurements are used in the diagnosis and treatment of electrolyte and metabolic disorders such as cystic fibrosis and diabetic acidosis. The GemLyte Calcium Assay is intended to measure the ionized calcium level in whole blood, plasma and serum. Calcium measurements are used in the diagnosis and treatment of parathyroid disease, a variety of bone diseases, chronic renal disease and tetany (intennittent muscular contractions or spasms). The GemLyte Lithium Assay is intended to measure lithium (from the drug lithium carbonate) in whole blood, plasma and serum. Measurements of lithium are used to assure that the proper drug dosage is administered in the treatment of patients with mental disturbances, such as manic-depressive illness (bipolar disorder).
Prescription Use X And/Or Over the Counter Use
(21 CFR Part 801 Subpart D)
(21 CFR Part 801 Subpart C)
Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety
510(k) -tg2:o.
DKA Order Set.xls
http://druginfo.goldstandard.com/direct/getmono.asp?caller=esmd